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Bisphenol A (BPA) is a monomer of poly-
carbonate plastics that is used in numerous 
consumer products, including food and water 
containers, baby bottles, linings of metal food 
and beverage cans, medical tubing, epoxy res-
ins, and dental fillings (Welshons et al. 2006). 
Small amounts of BPA can be liberated from 
incompletely polymerized polycarbonates or 
via partial hydrolysis, especially upon heating 
(Le et al. 2008). Decades of continuous release 
of free BPA into food, beverages, and the envi-
ronment have resulted in a widespread human 
exposure to this chemical. Many studies in 
the United States, Europe, and Japan have 
documented BPA levels ranging from 0.2 to 
10 ng/mL (~ 0.5–40 nM) in adult and fetal 
human serum (Welshons et al. 2006) as well 
as in breast milk (Kuruto-Niwa et al. 2007). 
Being lipophilic, BPA can also accumulate in 
fat, and detectable levels of BPA have been 
found in half of breast adipose tissue samples 
examined (Fernandez et al. 2007).
Given the structural similarity of BPA 
to the potent estrogenic compound diethyl-
stilbestrol, BPA’s ability to promote carcino-
genesis has long been suspected (Keri et al. 
2007). Studies with rodents have revealed that 
early-life exposure to BPA causes increased 
susceptibility to mammary and prostate 
tumorigenesis (Prins et al. 2007; Soto et al. 
2008), but there is less evidence for carcino-
genic activity of BPA when administered to 
adult animals. Studies with human breast 
cancer cells have yielded inconsistent data 
with respect to the mitogenic, apoptotic, and 
transcriptional properties of BPA (Dairkee 
et al. 2008; Diel et al. 2002; Singleton et al. 
2006; Soto et al. 1995). This inconsistency is 
attributed to the wide variations in BPA doses 
used, some of which are at micromolar levels. 
BPA often exhibits a U-shaped or an inverted 
U-shaped dose–response curve. Consequently, 
extrapolation from an action, or lack of action, 
of BPA at high doses to its presumed bioactiv-
ity at low doses is unwarranted. Thus, to sup-
port the argument that BPA poses risks to 
human health, it is necessary to establish its 
effectiveness at environmentally relevant con-
centrations (the low nanomolar range).
The mechanism by which BPA exerts it 
biological actions is enigmatic. The binding 
affinity of BPA to estrogen receptor-α (ERα) 
or ERβ is 10,000- and 1,000-fold lower than 
that of estradiol (E2), respectively (Kuiper et al. 
1998). This suggests that BPA should mimic 
or compete with endogenous estrogens only at 
the micromolar range. Yet, BPA at nanomolar 
doses often displays activities that are similar 
to those of E2 (Watson et al. 2005; Welshons 
et al. 2006). To reconcile this dilemma, 
several speculations have been proposed. One 
view is that BPA binds differently within the 
ligand-binding domain of ERα or ERβ and 
recruits a dissimilar set of co-regulators (Safe 
et al. 2002). Other investigators maintain that 
BPA elicits its responses via non  classical ERs, 
including membrane-anchored ERs (Watson 
et al. 2005), G-protein–coupled receptor 30 
(GPR30; Thomas and Dong 2006), and mem-
bers of the estrogen-related receptors (ERRs) 
such as ERRγ, which has a high binding affin-
ity to BPA (Okada et al. 2008).
Although most studies to date have exam-
ined whether BPA stimulates breast cancer cell 
proliferation, its potential effects on chemo-
therapeutic efficacy have received little atten-
tion. Chemotherapy, alone or in combination 
with hormonal or targeted therapy, remains 
the mainstay treatment in metastatic breast 
disease. A wide variety of anti  cancer drugs are 
available, including doxorubicin, cisplatin, and 
vinblastine. Most regimens combine agents 
that act by different mechanisms to improve 
efficacy. Although treatment of breast cancer 
patients with these anti  cancer drugs has shown 
good success, tumor resistance remains a major 
obstacle. Some tumors are intrinsically resistant 
to certain drugs, whereas others can acquire 
resistance after treatment. Although the effects 
of environmental pollutants on drug transport-
ers as well as on metabolic and detoxifying 
enzymes have been explored to some extent 
(Brockmoller et al. 2000; Chen et al. 1998; 
Han and Zhang 2004), there is no information 
on whether endocrine disruptors can modulate 
the responsiveness of breast cancer cells to anti-
cancer drugs.
The objectives of this study were to 
a) compare the effects of low doses of BPA 
on cisplatin, doxorubicin, and vinblastine 
cytotoxicity in the estrogen-responsive T47D 
breast cancer cells; b) examine whether BPA 
exerts similar effects on the estrogen-insensitive 
MDA-MB-468 breast cancer cells; c) compare 
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Ba c k g r o u n d: Resistance to chemotherapy is a major problem facing breast cancer patients, and 
identifying potential contributors to chemoresistance is a critical area of research. Bisphenol A 
(BPA) has long been suspected to promote carcinogenesis, but the high doses of BPA used in many 
studies generated conflicting results. In addition, the mechanism by which BPA exerts its biological 
actions is unclear. Although estrogen has been shown to antagonize anticancer drugs, the role of 
BPA in chemoresistance has not been examined.
oB j e c t i v e: The objective of our study was to determine whether BPA at low nanomolar concentra-
tions opposes the action of doxorubicin, cisplatin, and vinblastine in the estrogen receptor-α (ERα)-
positive T47D and the ERα-negative MDA-MB-468 breast cancer cells.
Me t h o d s : We determined the responsiveness of cells to anticancer drugs and BPA using the 
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) cytotoxicity assay. Specific 
ERα and ERβ inhibitors and real-time polymerase chain reaction were used to identify potential 
receptor(s) that mediate the actions of BPA. Expression of antiapoptotic proteins was assessed by 
Western blotting.
re s u l t s: BPA antagonizes the cytotoxicity of multiple chemotherapeutic agents in both ERα-
positive and -negative breast cancer cells independent of the classical ERs. Both cell types express 
alternative ERs, including G-protein–coupled receptor 30 (GPR30) and members of the estrogen-
related receptor family. Increased expression of antiapoptotic proteins is a potential mechanism by 
which BPA exerts its anticytotoxic effects.
co n c l u s i o n s: BPA at environmentally relevant doses reduces the efficacy of chemotherapeutic 
agents. These data provide considerable support to the accumulating evidence that BPA is hazardous 
to human health.
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expression of classical (ERα and ERβ) and 
non  classical (GPR30, ERRα, ERRβ, and 
ERRγ) ERs in the two cell lines; d) determine 
the effects of the ER antagonist ICI182,780 
(ICI) and the ERβ-specific antagonist 4-[2- 
phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]
pyrimidin-3-yl]phenol (PHTPP) on the abil-
ity of BPA to antagonize the cytotoxic effects 
of doxo  rubicin; and e) examine whether the 
chemo  resistant effects of BPA are mediated by 
altered expression of antiapoptotic/pro  apoptotic 
proteins of the Bcl-2 and survivin families.
Materials and Methods
Drugs and inhibitors. Doxorubicin (Sigma, 
St. Louis, MO), cisplatin (Sigma), and vin-
blastine (Biomol, Plymouth Meeting, PA) 
were dissolved in water at stock concentra-
tions of 1 mg/mL (doxorubicin and cisplatin) 
or 0.1 mg/mL (vinblastine). ICI and PHTPP 
(both from Tocris Bioscience, Ellisville, MO) 
were dissolved in dimethyl sulfoxide (DMSO; 
100 mM) and ethanol (50 mM), respectively. 
Drugs and inhibitors were diluted in culture 
medium immediately before treatment.
Cell lines and culture conditions. We 
obtained T47D and MDA-MB-468 cells 
from the American Type Culture Collection 
(Manassas, VA). T47D cells were maintained 
in RPMI medium (Hyclone, Logan, UT) 
supplemented with 10% fetal bovine serum 
(FBS; Hyclone), 5 µg/mL bovine insulin, 
10 mM HEPES, 1 mM sodium pyruvate, and 
50 µg/mL normocin (InvivoGen, San Diego, 
CA). MDA-MB-468 cells were cultured in 
low-glucose Dulbecco’s modified Eagle’s 
medium (DMEM; Hyclone) supplemented 
with 10% FBS and 50 µg/mL normocin. 
For all experiments, T47D cells were plated 
in phenol red–free RPMI with 5% charcoal-
stripped serum (CSS) and ITS+ supplement 
(1:200; BD Biosciences, Bedford, MA) and 
treated in RPMI with 3% CSS and ITS+. 
MDA-MB-468 cells were plated in phenol 
red–free DMEM supplemented with 3% CSS 
and treated in DMEM with 1% CSS.
Cytotoxicity assay. Cells were plated at a 
density of 6,000 or 8,000 cells/well in 96-well 
plates in plating medium. The next day, cells 
were incubated with BPA for 24 hr in treat-
ment medium. In the case of inhibitors, ICI 
and PHTPP were added to the cells 1 hr 
before BPA. After BPA treatment for 24 hr, 
the various drugs were added for an addi-
tional 1–4 days in the continuous presence 
of BPA. We determined cytotoxicity using 
3-(4,5-dimethyl  thiazol-2-yl)2,5-diphenyl 
tetra  zolium bromide (MTT). MTT was added 
at a final concentration of 0.5 mg/mL for 2 hr. 
After medium aspiration, the formazan dye 
was extracted with DMSO and absorbance 
was read at 570 nm using a plate reader (Bio-
Tek, Winooski, VT).
Western blotting. After treatment, we 
homogenized cells in buffer (10 nM Tris-HCl, 
5 mM EDTA, 50 nM NaCl, 50 mM sodium 
fluoride, 30 mM sodium pyrophosphate, 1% 
Triton-X, 200 µM sodium orthovanadate, 
1 mM phenyl  methyl  sulfonyl fluoride, 1 µg/mL 
pepstatin, 2 µg/mL leupeptin, 5 µg/mL apro-
tinin). The protein concentration was deter-
mined using the Pierce (Rockford, IL) BCA 
(bicinchoninic acid) protein assay. Cell lysates 
(40 µg protein) were electrophoresed onto 
12% or 15% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis gels. After transfer to 
polyvinyl difluoride membranes, samples were 
blocked in 5% dry milk and incubated over-
night with the following primary anti  bodies: 
Bcl-2, Bcl-xL, survivin (1:1,000 each; Cell 
Signaling, Danvers, MA), ERα (1:400; Santa 
Cruz Biotechnology, Santa Cruz, CA), ERβ 
Table 1. Human gene-specific primers for quantitative real-time reverse-transcriptase PCR.
Gene  Accession no.a  Forward primer (5´→3´)  Reverse primer (5´→3´)  Product size (bp)
ESR1  NM_000125  CAGGCACATGAGTAACAAAGG  CAAGGAATGCGATGAAGTAGAG  195
ESR2  NM_001437  CAGTTATCACATCTGTATGCGG  ACTCCATAGTGATATCCCGA  208
ESRRA  NM_004451  ACTGCAGGATGAGCTGG  TGCACAGAGTCTGAATTGG  185
ESRRB  NM_004452  CTGGTGTACGCTGAGGA  TACATGGAATCGGAGTTGG  172
ESRRG  NM_001438  CATATTCCAGGCTTCTCCA  GACAAGTTCATCCTCAAACGA  122
GPR30  NM_001039966  ACGAGACTGTGAAATCCGCAACCA  ATCAGGCTGGAGGTGCACTTGGAA  153
B2M  NM_004048  GGCATTCCTGAAGCTGAC  GAATCTTTGGAGTACGCTGG  114
Abbreviations: ESR1, ERα; ESR2, ERβ; ESRRA, ERRα; ESRRB, ERRβ; ESRRG, ERRγ (all three transcripts). Primer pairs were 
designed using the PerlPrimer (Marshall 2004) and are all intron-spanning pairs. 
aGenBank accession numbers (National Center for Biotechnology Information 2008). 
Figure 1. BPA protects T47D cells from several chemotherapeutic agents. Cells were treated with BPA for 24 hr, followed by increasing concentrations of doxo-
rubicin (Dox; A), cisplatin (Cis; B), or vinblastine (Vin; C) for an additional 96 hr. Cytotoxicity was determined by the MTT assay. Values are mean ± SE of six repli-
cates of a single experiment, repeated three times with similar results. 
*p < 0.05 compared with control. **p < 0.05 compared with the corresponding drug dose. 
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Figure 2. BPA antagonizes anticancer drugs in MDA-MB-468 cells. Cells were treated with BPA for 24 hr, followed by increasing concentrations of doxorubicin 
(Dox; A), cisplatin (Cis; B), or vinblastine (Vin; C) for an additional 96 hr. Cytotoxicity was determined by the MTT assay. Values are mean ± SE of six replicates of a 
single experiment, repeated three times with similar results. 
*p < 0.05 compared with control. **p < 0.05 compared with the corresponding drug dose.
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(1:3,000; Upstate, Danvers, MA), or β-actin 
(1:10,000; Sigma). After incubation with 
horseradish peroxidase–conjugated secondary 
antibody (Amersham, Piscataway, NJ), prod-
ucts were developed on film using SuperSignal 
chemiluminescence reagents (Pierce).
Real-time polymerase chain reaction 
(PCR). Total RNA was isolated using Tri-
Reagent (MRC, Cincinnati, OH) and cDNA 
was synthesized as previously described 
(Hugo et al. 2006). PCR was performed on 
200 ng cDNA using intron-spanning primers 
for ERα, ERβ, GPR30, ERRα, ERRβ, and 
ERRγ; we used β2-microglobulin (β2M) as 
a reference gene. Primer sequences are listed 
in Table 1. We performed quantitative real-
time PCR using Immolase heat-activated Taq 
DNA polymerase (Bioline, Taunton, MA). 
SYBR Green I (Invitrogen, Carlsbad, CA) 
was used for fluorometric product detection 
using a SmartCycler I cytometer (Cepheid, 
Sunnyvale, CA). Cycle parameters were 96°C 
for 15 min for polymerase activation, followed 
by 40 cycles of 95°C for 15 sec, 57°C for 
15 sec, and 72°C for 30 sec, with an optical 
read stage at 83.5°C for 6 sec. We confirmed 
product purity by DNA melting curve analy-
sis. After correction for β2M, fold changes 
in gene expression were calculated from the 
cycle threshold measurements as previously 
described (Pfaffl et al. 2002).
Data analysis. Statistical differences were 
determined by one-way analysis of variance 
followed by Newman-Keuls post hoc analysis. 
p-Values < 0.05 were considered significant. 
All experiments were performed at least three 
times.
Results
BPA protects T47D cells from chemothera-
peutic-induced cytotoxicity. We first exam-
ined the sensitivity of the estrogen-responsive 
T47D cells to selected anticancer drugs, and 
determined whether BPA protects the cells 
from drug-induced cytotoxicity. As shown 
in Figure 1, doxorubicin induced a dose-
dependent decrease in cell viability that was 
either completely or partially antagonized by 
a 24-hr pre  treatment with a low dose of BPA 
(1 nM). The cells were less sensitive to cispla-
tin, with the highest tested dose (400 ng/mL) 
decreasing viability by approximately 40%. 
BPA prevented drug-induced cytotoxicity at 
all tested cisplatin doses. The cytotoxic effects 
of vinblastine on T47D cells resembled that 
of doxorubicin. Pretreatment with BPA was 
highly effective only against the lowest dose of 
vinblastine (1 ng/mL). In all cases, BPA alone 
increased cell viability.
BPA antagonizes chemotherapeutic agents 
in MDA-MB-468 cells. We next examined 
whether BPA protected the estrogen-unre-
sponsive MDA-MB-468 cells from the same 
anticancer drugs (Figure 2). Similar to T47D 
cells, doxorubicin treatment resulted in a 
dose-dependent decrease in MDA-MB-468 
cell viability. BPA completely or partially pro-
tected the cells from all doses of doxorubi-
cin. MDA-MB-468 cells were significantly 
more sensitive to cisplatin than were T47D 
cells, with the 400 ng/mL dose of cisplatin 
inhibiting cell viability by > 80%. All doses of 
cisplatin were antagonized by a pre  treatment 
with BPA. BPA protected MDA-MB-468 
cells only from the lowest dose of vin  blastine. 
Unlike in T47D cells, BPA alone had no 
effect on cell viability.
BPA, at low nanomolar concentrations, 
protects cells from doxorubicin-induced cyto-
toxicity. The next experiment evaluated the 
ability of increasing, environmentally relevant 
doses of BPA to antagonize the cytotoxic 
effect of one dose of doxorubicin. Figure 3 
shows that BPA alone (1 nM or 10 nM) sig-
nificantly increased cell viability in T47D 
cells but not in MDA-MB-468 cells. In both 
cell types, doxorubicin treatment induced an 
approximately 35% decrease in cell viability. 
A 24-hr pretreatment with BPA at all doses 
examined completely protected the cells from 
doxorubicin-induced cytotoxicity.
The protective effects of BPA are not 
mediated via classical ERs. To determine if 
the protective effects of BPA involved ERα 
or ERβ, we used ICI, an antagonist of both 
receptors, as well as PHTPP, a specific ERβ 
antagonist. As shown in Figure 4A, neither 
ICI nor PHTPP had any effect by themselves 
Figure 3. Low doses of BPA protect T47D (A) and MDA-MB-468 (B) cells from doxorubicin (Dox) treatment. 
Cells were treated with increasing doses of BPA for 24 hr, followed by doxorubicin for an additional 24 hr. 
Cytotoxicity was determined by the MTT assay. Values are mean ± SE of six replicates of a single experi-
ment, repeated three times with similar results. 
*p < 0.05 compared with control. **p < 0.05 compared with doxorubicin.
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Figure 4. BPA mediates its protective effects independent of the classical ERs. T47D (A) and MDA-MB-468 
(B) cells were treated with 100 nM ICI or PHTPP 1 hr before BPA (10 nM); after 24 hr pretreatment with 
BPA, cells were exposed to doxorubicin (Dox; 25 ng/mL) for an additional 24 hr. Cytotoxicity was deter-
mined by the MTT assay. Values are mean ± SE of six replicates of a single experiment, repeated three 
times with similar results. T47D (C) and MDA-MB-468 (D) cells were treated with 100 nM ICI or PHTPP for 
1, 4, or 48 hr. Western blots were probed for ERα or ERβ; β-actin served as a loading control. Shown are 
representative blots, repeated at least three times.
*p < 0.05 compared with control. **p < 0.05 compared with doxorubicin. 
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on T47D or MDA-MB-468 cell viability. 
Furthermore, the ability of BPA to antago-
nize doxorubicin-induced cytotoxicity in either 
cell line was not altered in the presence of ICI 
or PHTPP. Using Western blotting, we next 
probed for both ERα and ERβ in T47D and 
MDA-MB-468 cells treated for 1, 4, or 48 hr 
with the above inhibitors. Figure 4B demon-
strates that T47D cells, but not MDA-MB-468 
cells, express ERα, whereas both cell types 
express ERβ. Treatment with ICI caused a 
time-dependent decrease in ERα expression in 
T47D cells, reducing it to an undetectable level 
by 48 hr. On the other hand, ERβ expression 
in MDA-MB-468 cells increased at 4 hr and 
decreased after 48 hr in response to ICI treat-
ment. PHTPP had no effect on ERα, increased 
the expression of ERβ in T47D cells, and had 
no effect on ERβ in MDA-MB-468 cells.
Relative receptor expression in T47D and 
MDA-MB-468 cells. Using real-time PCR, 
we compared the expression of several puta-
tive ERs in the two cell lines, as percentage 
of ERα expression in T47D cells. Figure 5 
shows that the expression of ERβ was similar 
in the two cells lines, being < 1% that of ERα. 
ERRα is the most highly expressed of the 
alternative receptors in both cell lines, near-
ing 10% of ERα in T47D cells. The expres-
sion levels of GPR30 and ERRγ are similar in 
T47D cells, with ERRγ slightly higher than 
GPR30 in MDA-MB-468 cells. ERRβ was 
undetectable in both cell lines.
BPA may promote chemoresistance by 
altering antiapoptotic proteins. We next 
explored the effects of BPA and doxo  rubicin 
on the expression of several pro  survival pro-
teins. As shown in Figure 6, treatment of 
T47D cell with BPA for 24 hr increased both 
Bcl-2 and Bcl-xL expression. BPA and doxo-
rubicin alone increased expression of survivin, 
but their combination had no further effect. 
Both doses of doxorubicin caused a small 
decrease in Bcl-2 expression, which was par-
tially prevented when cells were pretreated 
with BPA. In MDA-MB-468 cells, Bcl-2 
expression was higher when cells were exposed 
to 75 ng/mL doxorubicin and BPA compared 
with 75 ng/mL doxorubicin alone. BPA alone 
did not increase the expression of Bcl-xL in 
MDA-MB-468 cells. In both cell lines, Bcl-xL 
expression was higher in cells treated with 
150 mg/mL doxorubicin and BPA compared 
with 150 ng/mL doxorubicin alone. Survivin 
expression was increased in both cell types in 
response to BPA or doxorubicin alone but was 
not further augmented by their combination.
Discussion
This is the first report that BPA antagonizes 
chemotherapeutic agents in both ERα-positive 
and -negative breast cancer cells. Importantly, 
unlike some previous studies that have used 
micro  molar concentrations of BPA, we 
obtained our data using low nano  molar con-
centrations, which are rele  vant to human 
exposure levels. BPA confers chemo  resistance 
to the anticancer drugs doxorubicin, cispla-
tin, and vinblastine, which act by different 
mechanisms. As judged by specific ERα/ERβ 
antagonists, BPA does not appear to mediate 
its effects through either ERα or ERβ. Given 
that both cell lines express nonclassical ERs 
such as GPR30 and members of the ERR fam-
ily, these could serve as putative BPA receptors. 
The ability of BPA to alter the expression of 
Bcl-2 and Bcl-xL suggests a potential mecha-
nism by which it confers chemoresistance in 
the two breast cancer cell lines.
We postulated that BPA might play a role 
in chemoresistance based on reports that E2 
antagonizes anti  cancer drugs. For example, 
taxol-induced cytotoxicity in MCF-7 breast 
cancer cells was abrogated by 0.1 µM E2 
(Huang et al. 1997). This was confirmed in 
a later study implicating JNK activation in 
the modulation of apoptosis and E2 protec-
tion (Razandi et al. 2000). In addition, E2 
antagonizes doxorubicin-induced cytotox-
icity in MCF-7 cells (Teixeira et al. 1995). 
Our data show that BPA protects T47D cells 
from several anti  cancer drugs. More unex-
pected was the effect of BPA on the estrogen-
unresponsive MDA-MB-468 cells, raising 
the prospect that ERα does not mediate the 
chemoresistant effects of BPA.
The few reports on the effects of BPA on 
mito  genesis have used the ER-positive MCF-7 
cells. Olsen et al. (2003) observed increased 
MCF-7 cell proliferation in response to BPA, 
with a relative proliferative potential 60,000 
times lower than that of E2. Samuelsen et al. 
(2001) further confirmed such effects of BPA; 
their MCF-7 data are a prime example of an 
inverted U-shaped curve that is often observed 
when treating cells with increasing doses of 
BPA. In that study, cell proliferation was 
unchanged in the presence of 10 nM BPA, 
increased > 40% with 100 nM BPA, peaked 
with 1 µM BPA, and declined at higher doses. 
These studies are in agreement with our data, 
which show an approximate 25% increase 
in cell viability in T47D cells in response to 
BPA. Despite the lack of a mitogenic effect 
of BPA in MDA-MB-468 cells, we observed 
its ability to antagonize the anticancer drugs 
with as little as 0.01 nM BPA.
Of particular interest is the ability of BPA 
to antagonize the cytotoxic effects of three 
chemotherapeutic agents that induce cell 
death by different mechanisms. Doxorubicin 
causes DNA damage by chelating metal ions, 
generating free radicals, and inhibiting topo-
isomerase, thereby blocking transcription 
(Aubel-Sadron and Londos-Gagliardi 1984). 
Cisplatin, a platinum-based compound, causes 
DNA intrastrand cross-linking and inhib-
its replication (Stewart 2007). Vinblastine 
acts by interfering with microtubule dynam-
ics, resulting in mitotic arrest and cell death 
(Toso et al. 1993). As mentioned above, E2 
Figure 5. T47D and MDA-MB-468 cells express sev-
eral types of ERs, as determined by real-time PCR. 
Both cell lines express ERβ, as well as nonclassi-
cal ERs such as GPR30, ERRα, and ERRγ. Data are 
percentages of ERα expression in T47D cells after 
corrections for β2M. Values are mean ± SE of five 
separate experiments.
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control. Shown are representative blots, repeated at least three times.
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protects against microtubule-altering and 
DNA-damaging drugs (Huang et al. 1997; 
Teixeira et al. 1995). Thus, drugs with differ-
ent intra  cellular targets may have a common 
mechanism for inducing cell death. Future 
studies should examine whether BPA protects 
cells from death ligands that induce apoptosis 
by binding to pro  apoptotic death receptors.
BPA weakly competes with 17β-E2 in 
binding to the ER. Using a cell-based tran-
scription assay with a reporter gene, Hiroi 
et al. (1999) reported that BPA exhibits ago-
nistic activity when signaling through ERβ 
but has both agonistic and antagonistic activ-
ity when inter  acting with ERα. Whereas 
T47D cells express both ERα and ERβ, 
MDA-MB-468 cells have long been used as 
a model for ER-negative breast cancer. We 
show that MDA-MB-468 cells express ERβ 
protein, whose levels can be modulated by 
treatment with ICI or PHTPP. Like others 
(Fan et al. 2003; Long and Nephew 2006), 
we show that ICI rapidly and dramatically 
degraded the ERα protein, suggesting that the 
use of ICI is comparable with targeting the 
receptor with small interfering RNA (siRNA). 
The finding that BPA exerted its anticytotoxic 
effects when ERα or ERβ were inhibited sug-
gests that BPA activates a nonclassical ER(s).
Nonclassical ERs include GPR30 and 
members of the ERR family: ERRα, ERRβ, 
and ERRγ. BPA binds to GPR30 with a 50% 
inhibitory concentration (IC50) of 630 nM, 
compared with E2 with an IC50 of 17.8 nM 
(Thomas and Dong 2006). Interestingly, 
ICI binds to GPR30 and acts as an agonist 
(Prossnitz et al. 2007). Although 17β-E2 does 
not bind to members of the ERR family, ERRs 
can bind to functional estrogen-responsive 
elements in ER target genes (Huppunen and 
Aarnisalo 2004). Among the ERRs, BPA binds 
strongly to ERRγ, with a dissociation constant 
(KD) of 5.5 nM, a much more environmentally 
relevant dose than that needed to bind to ERα 
or ERβ (Matsushima et al. 2007). This makes 
ERRγ the most likely candidate for mediat-
ing the protective effects of BPA. Importantly, 
ERRγ mRNA level was significantly elevated 
3.9-fold in breast tumors relative to normal 
mammary epithelial cells (Ariazi and Jordan 
2006). We found that both T47D and 
MDA-MB-468 cells express GPR30, ERRα, 
and ERRγ, whereas ERRβ was undetectable. 
These data identified potential receptors that 
should be pursued using approaches such as 
siRNA to determine which receptor(s) medi-
ates the chemo  protective effects of BPA.
The mechanisms underlying chemo-
resistance include altered expression of 
proapoptotic/antiapoptotic proteins, increased 
activity of membrane transporters such as 
P-glycoprotein, the status of tumor suppres-
sors, and the efficiency of DNA repair pro-
cesses. The anti  apoptotic Bcl-2 and Bcl-xL 
proteins and survivin, a pro  survival inhibitor of 
apoptosis, are major players in tumor growth 
and resistance to cytotoxic insults. Estrogen 
increases Bcl-2 protein expression in MCF-7 
cells, with cells transfected with Bcl-2 antisense 
twice as sensitive to doxo  rubicin treatment in 
the presence of estrogen compared with con-
trols (Teixeira et al. 1995). Another study 
suggested that increased Bcl-2 in response to 
estrogen protects cells from taxol-induced cyto-
toxicity (Huang et al. 1997). Our data indi-
cate that up-regulation of Bcl-2 and Bcl-xL is 
a plausible mechanism by which BPA confers 
resistance to doxo  rubicin and possibly other 
anti  cancer drugs. The survivin data agree with 
another study that found increased expression 
of this protein after doxorubicin treatment 
(Tirro et al. 2006). However, the contributions 
of survivin are less critical when proteins such 
as Bcl-2 and Bcl-xL, which are upstream of 
  survivin, mediate survival.
In conclusion, we have shown that low 
doses of BPA confer chemoresistance to mul-
tiple anticancer drugs, possibly by increasing 
expression of antiapoptotic Bcl-2 proteins. 
Importantly, we observed the effects of BPA 
in a cell line lacking ERα, indicating that BPA 
acts via nonclassical receptors. These data high-
light a previously unrecognized function of 
BPA in cancer management, thereby adding 
strong support to the growing recognition of 
the adverse effects of BPA on human health.
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